G&E’s Plant Bioactivity and Mechanism Research Center was approved by the National Science Council. With research professionals and equipment on par with leading academic institutions, the company is recognized as one of Taiwan’s few specialized botanical new drug development centers. Over the years, G&E has successfully completed multiple government‑funded projects and academia‑industry collaborations. Notably, its new drug SR‑T100 gel has been approved by the Ministry of Health and Welfare for human clinical trials, completed Phase III clinical trials, and received FDA approval for Phase II clinical trials in the United States for the treatment of actinic keratosis and condyloma acuminatum. The company is also advancing development of an injectable formulation for treating malignant ascites in terminal cancer patients. In addition, G&E operates government‑certified facilities, including a botanical extraction plant, food supplement production lines, skincare product manufacturing, and a PIC/S GMP pharmaceutical plant. From contracted cultivation and quality analysis to mass production, all processes are managed in‑house, enabling the company to deliver natural botanical supplements, plant‑based functional cosmetics, pharmaceuticals, and clinical trial medications with consistent quality and reliability.
World-Class R&D and Clinical Milestones
G&E’s Plant Bioactivity and Mechanism Research Center is officially recognized by Taiwan’s National Science and Technology Council (NSTC). Equipped with state-of-the-art infrastructure and staffed by top-tier scientific professionals on par with leading academic institutions, G&E stands as one of Taiwan’s premier hubs dedicated to botanical new drug development. Over the years, the company has built a robust portfolio by successfully executing numerous government-sponsored research initiatives and strategic industry-academia collaborations.
The company's clinical excellence is best demonstrated by its flagship botanical pipeline, the SR-T100 gel. This investigational drug has successfully completed Phase III human clinical trials under the approval of the Taiwan Food and Drug Administration (TFDA). Furthermore, it has secured Investigational New Drug (IND) clearance from the U.S. FDA to conduct Phase II clinical trials for the treatment of actinic keratosis and condyloma acuminatum. Concurrently, G&E is advancing an innovative injectable formulation specifically designed to target malignant ascites in advanced-stage cancer patients.
Vertically Integrated GMP Manufacturing
To support its rigorous R&D and commercialization efforts, G&E operates a fully integrated, government-certified manufacturing infrastructure. This encompasses a rigorous PIC/S GMP pharmaceutical plant, a standardized botanical extraction facility, and highly controlled production lines for dietary supplements and functional dermocosmetics.
By managing the entire supply chain completely in-house—from standardized contract cultivation and strict quality control analysis to commercial-scale mass production—G&E ensures absolute traceability. This robust vertical integration empowers the company to consistently deliver pharmaceutical-grade clinical trial materials, natural botanical supplements, and functional skincare products with unparalleled reliability and global quality compliance.
Financial Robustness and Corporate Governance
Technological Breakthroughs and Clinical Focus
At the core of G&E's mission is the clinical advancement of its flagship oncology drug, SR-T100. Concurrently, the company successfully applies its cutting-edge pharmaceutical processing technologies to overcome historical hurdles in drug bioavailability and therapeutic efficacy. A prime example is G&E’s enhanced Silymarin formulation. By achieving industry-leading dissolution rates that strictly comply with international pharmacopeial standards, this formulation maximizes oral absorption and unlocks significant therapeutic potential for managing complex hepatic, biliary, and renal conditions. These concrete scientific achievements are rapidly propelling G&E's proprietary technologies onto the global biopharmaceutical stage.
Benchmark for End-to-End Biotech Excellence
Driven by rigorous scientific inquiry and evidence-based pragmatism, G&E ensures that every botanical product it develops is innovative, clinically validated, and technologically advanced. Supported by comprehensive empirical data and external regulatory endorsements, G&E has solidified its position as a benchmark enterprise in Taiwan’s botanical biopharmaceutical sector. As one of the elite few companies possessing true full-spectrum capabilities—from initial botanical drug discovery seamlessly through to commercial-scale mass production—G&E is dedicated to building a trusted global brand, delivering uncompromising quality to consumers, and contributing meaningfully to the global biotech economy.
Core Technologies and Strategic Advantages
